Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Durgadevi Ravillah

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Oncology Reports|May 28, 2013
Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 ratsNaveena B Janakiram, Altaf Mohammed, Durgadevi Ravillah, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 13, 2013
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesisDurgadevi Ravillah, Altaf Mohammed, Li Qian, et al.
Oncology Reports|February 21, 2025
[Corrigendum] Chemopreventive effects of PBI‑Se, a selenium‑containing analog of PBIT, on AOM‑induced aberrant crypt foci in F344 ratsNaveena B Janakiram, Altaf Mohammed, Durgadevi Ravillah, et al.
British Journal of Haematology|April 22, 2016
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cellsArghya Ray, Durgadevi Ravillah, Deepika S Das, et al.
Nature Communications|January 29, 2026
VSIG10L is a major determinant of esophageal homeostasis and inherited predisposition to Barrett's esophagusDurgadevi Ravillah, Salendra Singh, Ramachandra M Katabathula, et al.
Gastroenterology|July 23, 2022
The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett's NeoplasiaSrividya Venkitachalam, Deepak Babu, Durgadevi Ravillah, et al.
Gastroenterology|February 16, 2019
Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal CancerAndrew E Blum, Srividya Venkitachalam, Durgadevi Ravillah, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Oncology Reports|May 28, 2013
Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 ratsNaveena B Janakiram, Altaf Mohammed, Durgadevi Ravillah, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 13, 2013
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesisDurgadevi Ravillah, Altaf Mohammed, Li Qian, et al.
Oncology Reports|February 21, 2025
[Corrigendum] Chemopreventive effects of PBI‑Se, a selenium‑containing analog of PBIT, on AOM‑induced aberrant crypt foci in F344 ratsNaveena B Janakiram, Altaf Mohammed, Durgadevi Ravillah, et al.
British Journal of Haematology|April 22, 2016
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cellsArghya Ray, Durgadevi Ravillah, Deepika S Das, et al.
Nature Communications|January 29, 2026
VSIG10L is a major determinant of esophageal homeostasis and inherited predisposition to Barrett's esophagusDurgadevi Ravillah, Salendra Singh, Ramachandra M Katabathula, et al.
Gastroenterology|July 23, 2022
The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett's NeoplasiaSrividya Venkitachalam, Deepak Babu, Durgadevi Ravillah, et al.
Gastroenterology|February 16, 2019
Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor-β and JNK Signaling Pathways in Esophageal CancerAndrew E Blum, Srividya Venkitachalam, Durgadevi Ravillah, et al.
Pageof 1